Neutralizing antibodies (NAbs) have significant preventive and therapeutic effects. They mainly target the RBD region and can block the binding site of COVID-19 to the ACE2 receptor. COVID-19 NAbs are a low contamination risk and highly specific, which play a crucial role in the research of COVID-19 treatments. Meanwhile,
The nucleocapsid (N) is a major structural protein of SARS-CoV-2. It is highly conservative, providing an ideal marker for immunodiagnosis. Fapon self-developed monoclonal antibodies have high sensitivity, specificity, and batch-to-batch consistency, with no cross-reactivity with other pathogens (human coronaviruses, flu, pneumonia, etc.). Different application scenarios are supported with stable bulk
Recombinant SARS-CoV-2 Spike Protein Receptor Binding Domain from HEK293 cells. The antigens can be used for total antibodies detection to SARS-CoV-2 virus in double-antigen sandwich immunoassay. Our antigens are manufactured to the highest quality standards and are performance guaranteed for the applications listed on the detailed datasheets.
Creative Diagnostics team has tested hundreds of anti-nucleocapsid antibody pairs to recommend you the best pair with proven performance in commercially launched rapid antigen COVID-19 assays.
Principle: COVID-19 Antigen Rapid Test is a rapid membrane-based lateral flow immunoassay for the qualitative detection of SARS-CoV-2 antigens in human nasopharyngeal